Rokit Healthcare has received clinical approval to begin the first human kidney regeneration surgery using autologous omentum-derived cells combined with AI-assisted 3D bioprinting and robotic surgery, with trials starting July 2026. This represents a shift from chronic kidney disease management toward actual tissue regeneration, with potential to restore organ function rather than manage decline.
Key Points
- First human kidney regeneration surgery uses autologous omentum-derived cells
- AI-based 3D bioprinting combined with robotic surgical precision
- Four years of preclinical data supports safety and regenerative capacity
Longevity Analysis
Chronic kidney disease accelerates aging across multiple systems — it drives systemic inflammation, impairs detoxification capacity, and disrupts hormonal regulation and energy production. Rather than slowing decline through dialysis or transplantation, regenerative approaches that restore functional kidney tissue address the root mechanism. The use of autologous cells eliminates immunosuppression burden while the precision of AI-guided bioprinting with robotic deployment reduces surgical trauma and infection risk, creating conditions for actual tissue integration rather than rejection. Success here would establish a proof of concept for regenerating other vital organs that accumulate damage with age.
Original published by Longevity.Technology.